SESN - Sesen Bio, Inc.
| Previous Close | 1.4400 |
| Open | 1.4100 |
| Bid | 0.0000 x 3000 |
| Ask | 0.0000 x 900 |
| Day's Range | 1.4100 - 1.4900 |
| 52 Week Range | 0.6610 - 2.6000 |
| Volume | 1,872,001 |
| Avg. Volume | 3,416,212 |
| Market Cap | 148.773M |
| Beta (3Y Monthly) | 0.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5050 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.50 |
- Thomson Reuters StreetEvents•3 days ago
Edited Transcript of SESN earnings conference call or presentation 13-May-19 12:00pm GMT
Q1 2019 Sesen Bio Inc Earnings Call
- Zacks•4 days ago
Implied Volatility Surging for Sesen Bio (SESN) Stock Options
Investors need to pay close attention to Sesen Bio (SESN) stock based on the movements in the options market lately.
- Business Wire•6 days ago
Sesen Bio Announces Pricing of Public Offering of Common Stock and Warrants
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 20,410,000 shares of its common stock and warrants to purchase 20,410,000 shares of its common stock at a public offering price of $1.47 per share and accompanying warrant. The gross proceeds of the offering to the Company are expected to be approximately $30 million, before deducting the underwriting discounts and commissions and other estimated offering expenses and excluding gross proceeds from the exercise of any warrants.
- Benzinga•6 days ago
The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks Hitting 52-week highs on June 18) Abbott Laboratories (NYSE: ABT ) Arrowhead Pharmaceuticals ...
- Business Wire•7 days ago
Sesen Bio Announces Proposed Public Offering of Common Stock and Warrants
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. All of the shares of common stock and warrants to purchase shares of common stock to be sold in the offering will be offered by Sesen Bio.
- Business Wire•15 days ago
Sesen Bio Announces Successful Pre-BLA Meeting with FDA for Vicinium®
Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for patients with cancer, today announced that it has completed a successful Type B Pre-Biologics License Application (BLA) meeting regarding the approval path for Vicinium for the treatment of patients with high-risk, Bacillus Calmette-Guérin (BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC). The Company has reached alignment with the U.S. Food and Drug Administration (FDA) on an Accelerated Approval Pathway for Vicinium along with Rolling Review, and the Company expects to initiate submission of the BLA in the fourth quarter of 2019.
- Business Wire•18 days ago
Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Regulatory Update on Pre-BLA Meeting for Vicinium®
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Dr. Thomas Cannell, President and CEO will host a conference call on Monday, June 10, 2019 at 8:00 a.m. ET to provide an update on the Company’s meeting with the FDA on June 6, 2019. The webcast can be accessed in the Investor Relations section of the company's website at www.sesenbio.com. The replay of the webcast will be available in the investor section of the company’s website at www.sesenbio.com for 60 days following the call.
- Investopedia•26 days ago
Penny Stocks to Buy Using Technical Analysis for June 2019
Traders should look for short-term opportunities in penny stocks as macroeconomic events cast a shadow of uncertainty on the markets.
- Business Wire•last month
Sesen Bio Announces Acceptance of Analytical Comparability Plan by the U.S. Food and Drug Administration to Support the BLA and Commercialization of Its Lead Asset, Vicinium® for Non-Muscle Invasive Bladder Cancer
Sesen Bio (SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that the Company has completed its Type C CMC meeting and has reached agreement with the U.S. Food and Drug Administration (FDA) on the Analytical Comparability Plan, and that, subject to final comparability data to be provided in the BLA submission, no additional clinical trials to establish comparability are deemed necessary at this time. Based on the Company’s assessment of the global demand potential for Vicinium, Sesen Bio sought a commercial manufacturer with outstanding manufacturing quality, a proven track record with regulatory agencies, and the capacity to meet global demand forecasts.
- Zacks•last month
Options Traders Expect Huge Moves in Sesen Bio (SESN) Stock
Sesen Bio (SESN) needs investors to pay close attention to the stock based on moves in the options market lately.
- Business Wire•last month
Sesen Bio Reports First Quarter 2019 Financial Results and Updated, Preliminary Primary and Additional Secondary Endpoint Data from Phase 3 VISTA Trial for High-Risk Non-Muscle Invasive Bladder Cancer
Company Announces Confirmed Meetings with the U.S. Food and Drug Administration in May and June 2019 to Review Registration Strategy for Vicinium®
- ACCESSWIRE•2 months ago
Will the Good News for Vicinium Continue for Sesen Bio, They Will Tell Investors Soon
NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report ...
- Business Wire•2 months ago
Sesen Bio to Host Conference Call to Review First Quarter 2019 Financial Results and Updated Preliminary Data from Phase 3 VISTA Trial
Sesen Bio , a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Monday, May 13, 2019 at 8:00 a.m.
- ACCESSWIRE•3 months ago
Four Healthcare Stocks Getting a Boost on Thursday
CORAL GABLES, FL / ACCESSWIRE / March 28, 2019 / The healthcare stock market has been a hotbed of excitement in the first few months of 2019 as companies in the industry have focused their efforts on developing innovative technologies and treatments for consumers. Consumers depend and expect healthcare companies to invest in new forms of drug treatments and other aspects of the care experience so that, when a patient needs care, they don't have to look very far. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Arcturus Therapeutics Ltd (ARCT), Sesen Bio Inc (SESN), and Regulus Therapeutics Inc (RGLS) are 4 healthcare companies making moves on Thursday.
- GlobeNewswire•3 months ago
Positive Results and New Technology Give Rise to Antibody Dominance
POINT ROBERTS, Wash. and DELTA, British Columbia, March 27, 2019 -- Investorideas.com, a leading investor news resource covering biotech and pharma stocks releases a snapshot.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of SESN earnings conference call or presentation 4-Mar-19 1:00pm GMT
Q4 2018 Sesen Bio Inc Earnings Call
- Simply Wall St.•4 months ago
What Kind Of Shareholder Owns Most Sesen Bio, Inc. (NASDAQ:SESN) Stock?
Every investor in Sesen Bio, Inc. (NASDAQ:SESN) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insidersRead More...
- Business Wire•4 months ago
Sesen Bio Reports Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial
Company Announces Additional Key Primary and Secondary Endpoints Further Supporting Vicinium® Treatment Potential in High-Risk Non-Muscle Invasive Bladder Cancer
- Business Wire•4 months ago
Sesen Bio to Host Conference Call to Review Fourth Quarter and Full-Year 2018 Financial Results and Additional Preliminary Data from Phase 3 VISTA Trial
Sesen Bio , a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of people with cancer, today announced that Company management will host a conference call and webcast on Monday, March 4, 2019 at 8:00 a.m.
- ACCESSWIRE•5 months ago
Health Stocks Benefitting the Most from Rally
HENDERSON, NV / ACCESSWIRE / January 22, 2019 / The stock market reached a level toward the end of last year where investors and analysts feared a recession. Some of this fear was over a U.S. China trade ...
- Simply Wall St.•5 months ago
Sesen Bio, Inc. (NASDAQ:SESN): A Fundamentally Attractive Investment
Sesen Bio, Inc. (NASDAQ:SESN) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case of Read More...
- Business Wire•6 months ago
Sesen Bio Announces Positive Preliminary 12-Month Data from Registration Phase 3 VISTA Trial of Vicinium for Non-Muscle Invasive Bladder Cancer
Complete Response Rates from All Four Time Points in Carcinoma in Situ Patients In-line with Phase 2 Data
- ACCESSWIRE•6 months ago
4 Healthcare Stocks That Could Test December Highs
CORAL GABLES, FL/ ACCESSWIRE / December 27,2018 / As the new year is rapidly approaching, companies in the healthcare sector are working tirelessly to create and implement nuanced methods for treating patients with a myriad of diseases and ailments. From data-based care solutions to improved treatment options, Premier Health Group (PHGRF) (PHGI), Allscripts Healthcare Solutions Inc (MDRX), ZIOPHARM Oncology Inc (ZIOP), and Sesen Bio Inc (SESN) are 4 healthcare stocks worth paying attention to before the end of the year. Premier Health Group (PHGRF) (PHGI), a company dominating the telehealth sector of the healthcare industry, has enjoyed a strong month of bullish trading, with Company shares soaring well above the 30% mark in a 30-day period.
- Business Wire•6 months ago
Sesen Bio to Host Conference Call to Review Updated VISTA Trial Data in Non-Muscle Invasive Bladder Cancer
Sesen Bio, Inc. (SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of people with cancer, today announced that company management will host a conference call on Thursday, Jan. 3, 2018 at 8:30 a.m. ET to review updated data from its Phase 3 VISTA Trial of Vicinium™ for the treatment of patients with high-grade non-muscle invasive bladder cancer who have been previously treated with bacillus Calmette-Guérin. The webcast can be accessed in the Investor Relations section of the company's website at www.sesenbio.com. The replay of the webcast will be available in the investor section of the company’s website at www.sesenbio.com for 60 days following the call.
- Business Wire•7 months ago
Sesen Bio Appoints Drug Development Expert, Dennis Kim, M.D., MPH, as Chief Medical Officer
Sesen Bio, Inc. (SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of people with cancer, today announced the appointment of Dennis Kim, M.D., MPH, as chief medical officer. In this role, Dr. Kim will oversee the continued Phase 3 development of Vicinium, Sesen Bio’s lead targeted fusion protein, for patients with high-grade non-muscle invasive bladder cancer (NMIBC), as well as preparations for a marketing authorization submission and pre-commercial activities. “We are thrilled to welcome Dennis to the Sesen Bio team and look forward to leveraging his deep drug development experience, particularly as we approach both six and 12-month data readouts from our VISTA Trial of Vicinium,” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio.
